In the training set, BCL2, SPAG16, LRRC37A2, TGFBR2, ANKRD12, and MYC appeared to be the risky factors, apparently upregulated, while PXK, BTG1, EXT1, MYCBP2, and PAX5 were downregulated in high-risk DLBCL patients. This evidence concerns the gene MYCBP2 and diffuse large B-cell lymphoma.